In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV1 than long-acting beta-agonists plus inhaled corticosteroids

Mario Cazzola,Paola Rogliani

doi:10.1136/ebmed-2017-110726

In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV1 than long-acting beta-agonists plus inhaled corticosteroids

Mario Cazzola, Paola Rogliani

https://doi.org/10.1136/ebmed-2017-110726

Copy DOI

Journal: Evidence Based Medicine	Publication Date: Aug 11, 2017
Citations: 3

Affiliation: University of Rome Tor Vergata

#Chronic Obstructive Pulmonary Disease #Use Of Long-acting Muscarinic Antagonist + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Commentary on: Horita N, Goto A, Shibata Y, et al . Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Evidence Based Medicine

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.